HealthcareServices

Lung Cancer Liquid Biopsy Market Outlook 2026–2030: Key Business Drivers and Trends

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the lung cancer liquid biopsy market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Lung Cancer Liquid Biopsy Market in 2026, and what figure is it projected to hit by 2030?

The lung cancer liquid biopsy market size has demonstrated rapid expansion in recent years. This market is projected to expand from $1.12 billion in 2025 to $1.31 billion in 2026, at a compound annual growth rate (CAGR) of 17.0%. Factors contributing to its historical growth include increasing lung cancer incidence rates, limitations of tissue biopsy procedures, advancements in molecular diagnostics, availability of circulating biomarker technologies, and growth of oncology research activities.

The lung cancer liquid biopsy market is projected to experience swift expansion in the coming years. It is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. This growth during the forecast period stems from factors such as the increasing need for precision oncology solutions, the broadening of liquid biopsy’s clinical applications, the rising acceptance of companion diagnostics, the expanding integration of AI-driven data analysis, and an elevated emphasis on early cancer screening initiatives. Key trends for the forecast period encompass a greater uptake of non-invasive diagnostic techniques, increased utilization of NGS-based liquid biopsy tests, a heightened requirement for early cancer detection, the widening scope of personalized oncology diagnostics, and improved integration of bioinformatics platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

Which Drivers Are Affecting Market Participation In The Lung Cancer Liquid Biopsy Market?

The rising incidence of lung cancer is projected to drive the expansion of the lung cancer liquid biopsy market in the coming years. This disease, marked by the uncontrolled proliferation of abnormal cells in the lungs, primarily escalates due to persistent tobacco consumption, which exposes the lungs to carcinogens. Lung cancer liquid biopsy assists by detecting genetic mutations and tumor DNA associated with cancer in a blood sample, thereby enabling earlier diagnosis, selection of appropriate treatments, and effective monitoring of disease progression or therapeutic response. For example, a report from the American Cancer Society (ACS), a U.S.-based nonprofit organization, in January 2023, estimated that 238,340 individuals, including 117,550 men and 120,790 women, would be diagnosed with lung cancer in 2023, with 127,070 people expected to succumb to the illness. Thus, the increasing occurrence of lung cancer is fueling the growth of the lung cancer liquid biopsy market.

What Segment Classifications Make Up The Lung Cancer Liquid Biopsy Market?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

Which Trends Are Shaping Activity Within The Lung Cancer Liquid Biopsy Market?

Major companies operating in the lung cancer liquid biopsy market are concentrating on developing technological advancements, such as blood-based lung cancer screening tests. These innovations aim to improve early detection capabilities, enhance diagnostic accuracy, and enable non-invasive, real-time monitoring of tumor progression and treatment response. A blood-based lung cancer screening test is a non-invasive method that analyzes biomarkers in the bloodstream to identify the presence of lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology company, introduced FirstLook Lung. This blood-based liquid biopsy test is designed to aid in early lung cancer detection by leveraging fragmentomics to detect early lung cancer with high sensitivity and a 99.8% negative predictive value, making it a convenient and accessible first step for at-risk individuals. Its purpose is to enhance early detection, increase screening rates, and help direct further imaging resources to those most likely to benefit.

Which Major Industry Participants Are Leading The Lung Cancer Liquid Biopsy Market Growth?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lung Cancer Liquid Biopsy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Lung Cancer Diagnostic And Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795